1. [CASE 1 — QUESTION 1]
A 66-year-old man with type 2 diabetes managed on metformin has an HbA1c of 7.0 percent. Eighteen months ago he sustained an ischemic stroke, and he has documented coronary artery disease. He is overweight with a body mass index of 31. His clinician is deciding how to optimize his regimen with attention to his vascular risk. Considering current guidance, what is the most appropriate next pharmacologic step?
A) Make no change because his HbA1c is at goal and no further agent is warranted
B) Add a GLP-1 receptor agonist with proven cardiovascular benefit as a preferred second agent, because established atherosclerotic cardiovascular disease is an indication regardless of baseline HbA1c
C) Add a sulfonylurea as the preferred second agent for patients with vascular disease
D) Add a thiazolidinedione to improve insulin sensitivity and reduce stroke risk
E) Defer any second agent until the HbA1c exceeds 9 percent
ANSWER: B
Rationale:
In a patient with type 2 diabetes and established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is a preferred second agent after metformin, recommended regardless of baseline HbA1c because the indication is cardiovascular risk reduction rather than glycemic need.
Option A: Option A is incorrect because an at-goal HbA1c does not preclude adding an agent for cardiovascular benefit.
Option C: Option C is incorrect because a sulfonylurea is not the preferred second agent for cardiovascular benefit and lacks the outcome evidence of GLP-1 receptor agonists.
Option D: Option D is incorrect because a thiazolidinedione is not the guideline-preferred choice here and is not indicated for stroke risk reduction in this setting.
Option E: Option E is incorrect because the recommendation does not depend on the HbA1c crossing a higher threshold; it applies regardless of baseline HbA1c.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient, the clinician wants to choose an agent specifically backed by cardiovascular outcome trial evidence rather than glycemic potency alone. Which group of GLP-1 receptor agonists has demonstrated cardiovascular benefit in dedicated outcome trials?
A) Twice-daily exenatide and oral semaglutide only
B) Albiglutide and exenatide extended-release, both with clearly significant superiority
C) Only agents that have never been studied in cardiovascular outcome trials
D) Liraglutide (LEADER), subcutaneous semaglutide (SUSTAIN-6), and dulaglutide (REWIND), each with cardiovascular outcome trial evidence of benefit
E) Only DPP-4 inhibitors, which share the GLP-1 receptor agonist outcome profile
ANSWER: D
Rationale:
Liraglutide (LEADER), subcutaneous semaglutide (SUSTAIN-6), and dulaglutide (REWIND) each demonstrated reduction in major adverse cardiovascular events in dedicated cardiovascular outcome trials, and agents with proven cardiovascular benefit are the preferred choices in established atherosclerotic disease.
Option A: Option A is incorrect because twice-daily exenatide was not the agent demonstrating outcome superiority, and oral semaglutide is not the canonical outcome-benefit list for this purpose.
Option B: Option B is incorrect because exenatide extended-release in EXSCEL did not reach statistical significance, so pairing it with albiglutide as clearly significant superiority is inaccurate.
Option C: Option C is incorrect because several agents have been studied in cardiovascular outcome trials and shown benefit.
Option E: Option E is incorrect because DPP-4 inhibitors have not shown the cardiovascular benefit seen with GLP-1 receptor agonists and do not share that outcome profile.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient, a colleague asks how the cardiovascular benefit of GLP-1 receptor agonists is thought to arise mechanistically, given that the patient has atherosclerotic disease but no heart failure. Which characterization is most accurate?
A) The benefit is predominantly anti-atherosclerotic and anti-inflammatory, with a stroke-predominant reduction in major adverse cardiovascular events and no clear reduction in heart failure hospitalization
B) The benefit is driven mainly by reduction in heart failure hospitalization through cardiac unloading
C) The benefit is explained entirely by the degree of HbA1c lowering achieved
D) The benefit derives from glucosuria-mediated volume reduction
E) The benefit is attributable solely to weight loss with no vascular component
ANSWER: A
Rationale:
The cardiovascular benefit of GLP-1 receptor agonists is believed to be predominantly anti-atherosclerotic and anti-inflammatory, with a stroke-predominant reduction in major adverse cardiovascular events and without a clear reduction in heart failure hospitalization. This fits a patient with atherosclerotic disease and prior stroke.
Option B: Option B is incorrect because reduction in heart failure hospitalization through cardiac unloading characterizes SGLT-2 inhibitors, not GLP-1 receptor agonists.
Option C: Option C is incorrect because the benefit is not explained mainly by HbA1c lowering; evidence points to direct, non-glycemic effects.
Option D: Option D is incorrect because glucosuria-mediated volume reduction is an SGLT-2 inhibitor mechanism, not a GLP-1 receptor agonist one.
Option E: Option E is incorrect because the benefit is not attributable to weight loss alone; direct vascular and anti-inflammatory effects contribute.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient, the clinician reviews trial data and notes that cardiovascular event curves separated early. Which observation most strongly supports a direct pharmacological (non-glycemic) mechanism of benefit?
A) The benefit appeared only after the largest cumulative HbA1c differences had developed over years
B) The benefit disappeared entirely once patients were adjusted for statin use
C) Cardiovascular event curves diverged early, within months, before meaningful HbA1c differences emerged, and the benefit persisted after adjustment for glycemic change
D) The benefit was confined to patients who reached the very lowest fasting glucose values
E) The benefit correlated perfectly with each agent's glucose-lowering potency
ANSWER: C
Rationale:
Early divergence of cardiovascular event curves, within months and before meaningful HbA1c separation, together with persistence of benefit after adjustment for glycemic change, supports a direct pharmacological mechanism rather than a glucose-mediated one.
Option A: Option A is incorrect because the benefit emerged early rather than tracking the later cumulative HbA1c difference.
Option B: Option B is incorrect because the benefit is not abolished by adjustment for statin use.
Option D: Option D is incorrect because the benefit is not confined to patients achieving the lowest fasting glucose.
Option E: Option E is incorrect because cardiovascular benefit correlates only imperfectly with glycemic potency, which argues for a direct mechanism.
5. [CASE 2 — QUESTION 1]
A 54-year-old woman with type 2 diabetes prefers an oral therapy and is started on oral semaglutide. She asks exactly how to take it so that it works. Which instruction correctly reflects the absorption mechanism of this formulation?
A) Take it with a large meal so that food enhances its absorption
B) Take it with at least 240 mL of milk to protect the peptide from acid
C) Take it at bedtime with other medications to improve convenience
D) Take it with a fatty snack, which is required for the absorption enhancer to work
E) Take it on an empty stomach with up to 120 mL of water and wait at least 30 minutes before any food, other drink, or medication, because it relies on the absorption enhancer SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) to permeabilize the gastric mucosa
ANSWER: E
Rationale:
Oral semaglutide is co-formulated with the absorption enhancer SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate), which transiently permeabilizes the gastric mucosa to allow absorption; because its bioavailability is low and condition-sensitive, it must be taken on an empty stomach with no more than 120 mL of water and at least 30 minutes before any food, other drink, or medication.
Option A: Option A is incorrect because food impairs absorption rather than enhancing it.
Option B: Option B is incorrect because it must be taken with water only, not milk, and the volume limit is 120 mL.
Option C: Option C is incorrect because taking it at bedtime with other medications would impair the empty-stomach absorption requirement.
Option D: Option D is incorrect because a fatty snack is not required and would worsen absorption; the drug must be taken on an empty stomach.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient, in the third week she reports nausea and early satiety. She is worried something is wrong. What is the best explanation for these symptoms?
A) They indicate an allergic reaction to the drug requiring immediate discontinuation
B) They are mechanism-based effects arising from GLP-1 receptor-mediated slowing of gastric emptying and central area postrema activation, are dose-dependent, and typically diminish over weeks as gastric receptor tachyphylaxis develops
C) They indicate the drug has caused hypoglycemia and require urgent glucose
D) They reflect corrosive injury to the gastric lining from the tablet
E) They are unrelated to the drug and should prompt a search for an unrelated gastrointestinal illness
ANSWER: B
Rationale:
The nausea and early satiety are mechanism-based, arising from GLP-1 receptor-mediated slowing of gastric emptying and activation of the central area postrema; they are dose-dependent, most pronounced early, and typically diminish over weeks as gastric receptor tachyphylaxis develops.
Option A: Option A is incorrect because these are predictable pharmacologic effects, not an allergic reaction mandating discontinuation.
Option C: Option C is incorrect because the symptoms are not due to hypoglycemia, which GLP-1 receptor agonists do not cause as monotherapy.
Option D: Option D is incorrect because the nausea is not corrosive gastric injury from the tablet.
Option E: Option E is incorrect because the symptoms are directly attributable to the drug's pharmacology rather than an unrelated illness.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient, she completes the labeled titration but several weeks later still has nausea that interferes with her daily activities despite small low-fat meals. She wishes to retain the benefits if possible. What is the most appropriate next step?
A) Abruptly increase to the maximum dose to move past the symptoms faster
B) Continue unchanged and advise her the nausea will resolve regardless of duration
C) Add an indefinite proton pump inhibitor as the definitive remedy and change nothing else
D) Consider switching to a different agent within the class, since tolerability varies among agents, or slow the titration, and discontinue only if intolerable symptoms persist despite these measures
E) Switch immediately to insulin, since intolerance precludes any further use of the class
ANSWER: D
Rationale:
When intolerable nausea persists after adequate titration, tolerability varies among agents, so switching to a different agent within the class is a legitimate option, as is slowing the titration; discontinuation is reserved for when intolerable symptoms persist despite these adjustments. This preserves the possibility of retaining the benefits.
Option A: Option A is incorrect because abruptly maximizing the dose worsens the mechanism-based nausea.
Option B: Option B is incorrect because nausea that persists and impairs function warrants action rather than indefinite waiting.
Option C: Option C is incorrect because an indefinite proton pump inhibitor is not the defined remedy and changing nothing else ignores the distress.
Option E: Option E is incorrect because intolerance to one agent does not preclude the whole class; a within-class switch or slower titration should be tried first.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient, on reflection the clinician reviews how the initiation was handled to minimize gastrointestinal effects. Which approach represents the standard tolerability strategy for GLP-1 receptor agonists?
A) Initiate at the lowest recommended dose and titrate upward gradually according to the labeled schedule, advising small low-fat meals during escalation
B) Initiate at the full maintenance dose to reach steady state quickly
C) Initiate with a high-fat meal regimen to buffer the stomach
D) Initiate at a supratherapeutic dose and then taper downward
E) Split a once-weekly agent into daily fractions to lower each exposure
ANSWER: A
Rationale:
The standard tolerability strategy is to initiate at the lowest recommended dose and titrate upward gradually according to the labeled schedule, with advice to eat small, low-fat meals during escalation; this minimizes the mechanism-based gastrointestinal effects that peak early.
Option B: Option B is incorrect because starting at full maintenance dose maximizes intolerance.
Option C: Option C is incorrect because high-fat meals worsen nausea during escalation.
Option D: Option D is incorrect because starting supratherapeutically and tapering down is not the recommended approach and would worsen early symptoms.
Option E: Option E is incorrect because once-weekly agents are dosed weekly and are not split into daily fractions; the correct lever is gradual dose titration.
9. [CASE 3 — QUESTION 1]
A 59-year-old woman with type 2 diabetes on metformin alone is started on a once-weekly GLP-1 receptor agonist. She asks whether this drug, by itself, will cause low blood sugars. What is the most accurate answer regarding monotherapy?
A) Yes, because the drug stimulates insulin release continuously regardless of glucose
B) Yes, because it blocks hepatic glucose output entirely
C) No, because its insulin-secretory effect is strictly glucose-dependent, so at normal or low glucose it does not trigger enough insulin release to cause hypoglycemia
D) No, because it prevents the pancreas from making any insulin at all
E) Yes, because it directly increases renal glucose excretion
ANSWER: C
Rationale:
As monotherapy, GLP-1 receptor agonists do not cause hypoglycemia because their insulin-secretory effect is strictly glucose-dependent; at normal or low glucose the signal does not trigger sufficient insulin release.
Option A: Option A is incorrect because the effect is glucose-gated rather than continuous and glucose-independent.
Option B: Option B is incorrect because the drug suppresses, but does not entirely block, hepatic glucose output, and this is not the basis for the absence of hypoglycemia.
Option D: Option D is incorrect because the drug amplifies glucose-stimulated insulin secretion rather than preventing insulin production.
Option E: Option E is incorrect because increased renal glucose excretion is an SGLT-2 inhibitor mechanism and is not why GLP-1 receptor agonists avoid hypoglycemia.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient, several months later a sulfonylurea is added for additional glycemic control. Within two weeks she develops symptomatic hypoglycemia, having eaten less because of appetite suppression. What is the most appropriate management of this combination?
A) Stop the GLP-1 receptor agonist, since it is the agent directly producing glucose-independent insulin release
B) Reduce the sulfonylurea dose by approximately 25 to 50 percent and continue with glucose monitoring, because the non-glucose-gated sulfonylurea plus reduced intake produced the hypoglycemia
C) Increase the sulfonylurea dose to overcome the variability
D) Add prandial insulin to stabilize the glucose
E) Reduce the metformin dose, since metformin is the cause of the hypoglycemia
ANSWER: B
Rationale:
The hypoglycemia results from adding a non-glucose-gated sulfonylurea to a GLP-1 receptor agonist while food intake falls from appetite suppression; the appropriate step is to reduce the sulfonylurea dose by roughly 25 to 50 percent and continue with glucose monitoring.
Option A: Option A is incorrect because the GLP-1 receptor agonist acts in a glucose-dependent manner and is not the agent driving the lows.
Option C: Option C is incorrect because increasing the sulfonylurea would worsen hypoglycemia.
Option D: Option D is incorrect because adding prandial insulin would further increase hypoglycemia risk.
Option E: Option E is incorrect because metformin does not cause hypoglycemia, so reducing it would not address the problem.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient, the sulfonylurea is later stopped and basal insulin is begun for persistent hyperglycemia while she remains on the GLP-1 receptor agonist. She soon reports fasting glucose values in the low 60s mg/dL with morning shakiness. What is the most appropriate adjustment?
A) Discontinue the GLP-1 receptor agonist, since it causes fasting hypoglycemia on its own
B) Increase the basal insulin to stabilize the fasting glucose
C) Restart the sulfonylurea to smooth the glucose pattern
D) Make no change, since these fasting values are the intended target
E) Reduce the basal insulin dose by approximately 10 to 20 percent and titrate based on fasting glucose monitoring
ANSWER: E
Rationale:
When a GLP-1 receptor agonist is combined with basal insulin, the amplified glucose-dependent insulin effect plus reduced intake can cause hypoglycemia; with symptomatic fasting values in the low 60s, the appropriate step is to reduce the basal insulin by roughly 10 to 20 percent and titrate based on fasting glucose monitoring.
Option A: Option A is incorrect because the GLP-1 receptor agonist does not cause fasting hypoglycemia on its own; the insulin is the modifiable contributor.
Option B: Option B is incorrect because increasing basal insulin would worsen the hypoglycemia.
Option C: Option C is incorrect because restarting the sulfonylurea would add further hypoglycemia risk.
Option D: Option D is incorrect because symptomatic fasting values in the low 60s represent hypoglycemia, not an intended target.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient, a student asks why the GLP-1 receptor agonist amplifies insulin secretion only when glucose is elevated, given that it raises cyclic adenosine monophosphate (cAMP) regardless of glucose. Which explanation is correct?
A) cAMP is generated only when glucose is high, so at low glucose there is no signaling at all
B) The receptor switches to an inhibitory G protein at low glucose, abolishing cAMP
C) cAMP directly opens calcium channels by itself, so glucose is irrelevant to insulin release
D) cAMP and its effectors amplify an insulin-secretory process that still requires glucose metabolism to close ATP-sensitive potassium channels and trigger calcium influx; at low glucose this triggering step is absent, so the amplified machinery has nothing to amplify
E) Insulin granules exist only at high glucose, so at low glucose there is nothing to release
ANSWER: D
Rationale:
cAMP and its effectors (protein kinase A and EPAC2) amplify insulin secretion but do not trigger it; triggering requires glucose metabolism to close ATP-sensitive potassium channels, depolarize the cell, and open voltage-gated calcium channels. At low glucose this triggering step is absent, so the cAMP-amplified machinery has no triggered exocytosis to enhance, which explains the glucose-dependence.
Option A: Option A is incorrect because cAMP is in fact generated even at low glucose, as the premise states.
Option B: Option B is incorrect because the receptor does not switch to an inhibitory G protein at low glucose.
Option C: Option C is incorrect because cAMP does not by itself open calcium channels independent of the glucose-driven triggering step.
Option E: Option E is incorrect because beta cells maintain a releasable granule pool; the glucose-dependence reflects the triggering calcium signal, not an absence of granules.
13. [CASE 4 — QUESTION 1]
A 46-year-old woman with type 2 diabetes and obesity asks about a GLP-1 receptor agonist for weight and glucose control. Her father and sister have medullary thyroid carcinoma in the setting of multiple endocrine neoplasia type 2 (MEN2), and genetic testing confirmed she carries the familial RET mutation. What is the most appropriate decision?
A) Do not prescribe any GLP-1 receptor agonist, because a personal or family history of medullary thyroid carcinoma or MEN2 is an absolute (black-box) contraindication for the entire class
B) Prescribe the drug but monitor calcitonin every three months
C) Prescribe a reduced dose, since the contraindication applies only at full dose
D) Prescribe after a reassuring baseline thyroid ultrasound
E) Prescribe an exendin-4-based agent, since the warning applies only to human GLP-1-based agents
ANSWER: A
Rationale:
A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is an absolute, black-box contraindication that applies to the entire GLP-1 receptor agonist class; with this family history and a confirmed RET mutation, no agent should be prescribed.
Option B: Option B is incorrect because the contraindication is absolute and routine calcitonin monitoring does not make a contraindicated patient a candidate.
Option C: Option C is incorrect because the contraindication is not dose-dependent.
Option D: Option D is incorrect because a reassuring ultrasound does not lift the contraindication in this genetic and family context.
Option E: Option E is incorrect because the contraindication applies across the whole class, including exendin-4-based agents.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient, she asks where the thyroid warning comes from and whether everyone on these drugs needs thyroid blood tests. Which explanation is most accurate?
A) The warning is based on confirmed human medullary thyroid carcinoma caused directly by the drugs, so all patients require calcitonin monitoring
B) The warning is purely theoretical with no experimental basis at all
C) The warning arises from rodent studies in which GLP-1 receptor agonists caused dose-dependent C-cell hyperplasia and medullary thyroid carcinoma via calcitonin-secreting C cells; the human relevance is uncertain, and routine calcitonin monitoring is not recommended in the absence of specific risk factors
D) The warning means calcitonin must be checked weekly in every patient
E) The warning applies only to patients over age 70
ANSWER: C
Rationale:
The medullary thyroid carcinoma concern arises from rodent carcinogenicity studies in which GLP-1 receptor agonists produced dose-dependent C-cell hyperplasia and medullary thyroid carcinoma, attributed to stimulation of calcitonin-secreting thyroid C cells; the human relevance is uncertain, and routine calcitonin monitoring is not recommended in the absence of specific risk factors.
Option A: Option A is incorrect because the rodent findings have not been confirmed as direct human causation, and routine calcitonin monitoring is not advised for all patients.
Option B: Option B is incorrect because the warning has a clear experimental (rodent) basis.
Option D: Option D is incorrect because weekly calcitonin testing in every patient is not recommended.
Option E: Option E is incorrect because the concern is not limited to patients over a particular age threshold.
15. [CASE 4 — QUESTION 3]
Continuing with the discussion of contraindications, consider a different patient who has no thyroid history but did have one episode of acute pancreatitis two years ago with full recovery and no current pancreatic disease. How should this pancreatitis history be weighed for GLP-1 receptor agonist therapy?
A) It is an absolute contraindication that permanently bars the entire class, identical in weight to a medullary thyroid carcinoma history
B) It is a caution rather than an absolute contraindication in a patient without ongoing pancreatic disease; the drug may be used with awareness and discontinued if acute pancreatitis recurs
C) It has no clinical relevance whatsoever and need not be considered
D) It mandates lifelong calcitonin monitoring before therapy
E) It requires switching to an SGLT-2 inhibitor, which is contraindicated by pancreatitis instead
ANSWER: B
Rationale:
A history of pancreatitis is a caution rather than an absolute contraindication in a patient without ongoing pancreatic disease; GLP-1 receptor agonists may be used with awareness and discontinued if acute pancreatitis is confirmed. This contrasts with the absolute medullary thyroid carcinoma/MEN2 contraindication.
Option A: Option A is incorrect because prior pancreatitis is not equivalent to a medullary thyroid carcinoma history and is not an absolute permanent bar.
Option C: Option C is incorrect because the pancreatitis history is clinically relevant and should be considered, even though it is not an absolute contraindication.
Option D: Option D is incorrect because calcitonin monitoring relates to the thyroid concern, not pancreatitis.
Option E: Option E is incorrect because pancreatitis history does not mandate switching to an SGLT-2 inhibitor and is not a defining SGLT-2 inhibitor contraindication.
16. [CASE 4 — QUESTION 4]
Continuing with this patient on a GLP-1 receptor agonist who has achieved substantial weight loss, she develops episodic right upper quadrant pain after fatty meals. Which class-associated effect best explains this, and what is the appropriate initial step?
A) Drug-induced hemolysis; obtain a peripheral smear
B) Drug-induced nephrolithiasis; obtain a renal ultrasound for stones
C) Drug-induced pulmonary embolism; obtain a chest computed tomography angiogram
D) Drug-induced retinopathy; obtain a dilated eye examination
E) Reduced gallbladder motility increasing biliary lithogenicity, with an increased risk of cholelithiasis and cholecystitis particularly at higher doses and with greater weight loss; obtain a right upper quadrant biliary ultrasound
ANSWER: E
Rationale:
GLP-1 receptor agonists reduce gallbladder motility and increase biliary lithogenicity, raising the risk of cholelithiasis and cholecystitis, particularly at higher doses and with greater weight loss; episodic right upper quadrant pain after fatty meals warrants a right upper quadrant biliary ultrasound.
Option A: Option A is incorrect because hemolysis is not a recognized class effect and does not explain fatty-meal-related right upper quadrant pain.
Option B: Option B is incorrect because the biliary signal is cholelithiasis, not nephrolithiasis.
Option C: Option C is incorrect because pulmonary embolism is not the explanation for this biliary presentation.
Option D: Option D is incorrect because the symptoms are biliary, not visual, so an eye exam does not address them.
17. [CASE 5 — QUESTION 1]
A 64-year-old man with type 2 diabetes and chronic kidney disease (estimated glomerular filtration rate [eGFR] 36 mL/min/1.73m2 with albuminuria) needs additional glucose lowering, and his clinician prioritizes renal protection. Which GLP-1 receptor agonist choice is best supported by dedicated renal-outcome evidence?
A) Twice-daily exenatide, the most renally protective agent in the class
B) No GLP-1 receptor agonist, because the class is contraindicated at this eGFR
C) Any agent equally, since renal-outcome evidence does not differ within the class
D) Semaglutide, supported by the dedicated FLOW renal-outcome trial in type 2 diabetes with chronic kidney disease and requiring no renal dose adjustment at this eGFR
E) A DPP-4 inhibitor, which has superior dedicated renal-outcome evidence to any GLP-1 receptor agonist
ANSWER: D
Rationale:
Semaglutide is supported by the dedicated FLOW renal-outcome trial in patients with type 2 diabetes and chronic kidney disease and requires no renal dose adjustment at this eGFR, making it the best-supported choice when renal protection is the goal.
Option A: Option A is incorrect because exenatide is the renally cleared exception to avoid at low eGFR, not the most renally protective agent.
Option B: Option B is incorrect because the class is not contraindicated at an eGFR of 36; most agents are used across these stages.
Option C: Option C is incorrect because the dedicated renal-outcome evidence is agent-specific (FLOW with semaglutide).
Option E: Option E is incorrect because DPP-4 inhibitors do not have superior dedicated renal-outcome evidence to GLP-1 receptor agonists.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient, the clinician compares the renal handling of GLP-1 receptor agonists with that of other glucose-lowering agents. Which statement is most accurate regarding the class across stages of renal impairment?
A) Most GLP-1 receptor agonists require no dose adjustment across most stages of renal impairment, an advantage over metformin (restricted below an eGFR of 30) and sulfonylureas (metabolite accumulation)
B) All GLP-1 receptor agonists must be dose-reduced once the eGFR falls below 60
C) GLP-1 receptor agonists are all renally excreted intact and require the same renal threshold
D) GLP-1 receptor agonists are more renally restricted than metformin at every stage
E) GLP-1 receptor agonists must be stopped at any degree of albuminuria
ANSWER: A
Rationale:
Most GLP-1 receptor agonists require no dose adjustment across most stages of renal impairment, which is an advantage over metformin (restricted below an eGFR of 30) and sulfonylureas (whose metabolites can accumulate).
Option B: Option B is incorrect because the class does not uniformly require dose reduction below an eGFR of 60.
Option C: Option C is incorrect because the agents are not all renally excreted intact and do not share a single renal threshold; handling differs by structural class.
Option D: Option D is incorrect because GLP-1 receptor agonists are generally less renally restricted than metformin, not more.
Option E: Option E is incorrect because albuminuria itself does not mandate stopping the class; semaglutide in particular has renal-protective evidence in this setting.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient, suppose his eGFR later declines to 24 mL/min/1.73m2 while he is taking twice-daily exenatide. What is the most appropriate action regarding the exenatide?
A) Continue exenatide unchanged, since renal function does not affect it
B) Discontinue exenatide and, if a GLP-1 receptor agonist is still desired, switch to a human GLP-1-based agent that does not require renal dose adjustment, because exenatide is cleared renally to a greater degree and is generally avoided below an eGFR of 30
C) Double the exenatide dose to compensate for reduced elimination
D) Continue exenatide but add a loop diuretic to enhance its clearance
E) Switch to metformin, which is preferred at this eGFR
ANSWER: B
Rationale:
Exenatide is cleared renally to a greater degree than other agents in the class and is generally avoided when the eGFR falls below 30; at an eGFR of 24 it should be discontinued, with a switch to a human GLP-1-based agent that needs no renal dose adjustment if continued therapy is desired.
Option A: Option A is incorrect because exenatide handling is affected by renal function, which is why it is the class exception.
Option C: Option C is incorrect because increasing the dose with declining elimination raises exposure and risk.
Option D: Option D is incorrect because adding a loop diuretic is not a strategy to safely continue exenatide here.
Option E: Option E is incorrect because metformin is contraindicated below an eGFR of 30 and is not preferred at an eGFR of 24.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient, the clinician reviews how GLP-1 receptor activation contributes to renoprotection at the level of the nephron. Which mechanism is correct?
A) Inhibition of the sodium-glucose cotransporter-2, producing glucosuria
B) Stimulation of the renin-angiotensin-aldosterone system, raising intraglomerular pressure
C) Blockade of collecting-duct aquaporins, producing a free-water diuresis
D) Activation of the epithelial sodium channel, increasing sodium retention
E) Inhibition of the sodium-hydrogen exchanger 3 (NHE3) in the proximal tubule, producing natriuresis and reducing intraglomerular pressure, with anti-inflammatory effects in podocytes and mesangial cells
ANSWER: E
Rationale:
GLP-1 receptor activation reduces proximal tubular sodium reabsorption by inhibiting the sodium-hydrogen exchanger 3 (NHE3), producing natriuresis and lowering intraglomerular pressure, with additional anti-inflammatory effects in podocytes and mesangial cells contributing to renoprotection.
Option A: Option A is incorrect because sodium-glucose cotransporter-2 inhibition with glucosuria is the SGLT-2 inhibitor mechanism.
Option B: Option B is incorrect because the renoprotective effect lowers, rather than raises, intraglomerular pressure and is not mediated by stimulating the renin-angiotensin-aldosterone system.
Option C: Option C is incorrect because the mechanism is not blockade of collecting-duct aquaporins to cause a free-water diuresis.
Option D: Option D is incorrect because activating the epithelial sodium channel to retain sodium is the opposite of the natriuretic NHE3-inhibition effect.
21. [CASE 6 — QUESTION 1]
A 57-year-old man with long-standing type 2 diabetes presents with an HbA1c of 11.4 percent and documented moderate non-proliferative diabetic retinopathy on a recent dilated exam. A high-potency GLP-1 receptor agonist is planned. Which management approach best addresses the retinopathy concern?
A) Lower the HbA1c as rapidly as possible to protect the retina from ongoing glycemic injury
B) Withhold all glucose-lowering intensification indefinitely because treatment will damage the retina
C) Pace the glycemic correction to avoid a rapid HbA1c drop and arrange ophthalmologic evaluation before and during intensification, because rapid correction can transiently worsen pre-existing retinopathy
D) Proceed at maximum dose immediately, since the rate of glycemic change does not affect the retina
E) Substitute a DPP-4 inhibitor, which uniquely prevents retinopathy progression
ANSWER: C
Rationale:
Rapid HbA1c reduction can transiently worsen pre-existing diabetic retinopathy; with moderate retinopathy and a high baseline HbA1c, the appropriate approach is to pace the correction and arrange ophthalmologic evaluation before and during intensification.
Option A: Option A is incorrect because lowering HbA1c as rapidly as possible is precisely what risks transient retinopathy worsening.
Option B: Option B is incorrect because therapy should proceed, paced and with eye surveillance, rather than being withheld indefinitely.
Option D: Option D is incorrect because the rate of glycemic change is the relevant factor for retinopathy worsening.
Option E: Option E is incorrect because DPP-4 inhibitors do not uniquely prevent retinopathy progression; the issue is the pace of correction.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient, he asks why rapid improvement in his diabetes could temporarily harm his eyes. Which explanation correctly links the trial observation to the underlying principle?
A) In SUSTAIN-6, semaglutide was associated with worsening diabetic retinopathy attributed to rapid HbA1c reduction, the same phenomenon seen with early intensive insulin therapy in the DCCT (Diabetes Control and Complications Trial), where acute glycemic correction transiently destabilizes ischemic retinal vasculature
B) The drug is directly toxic to retinal photoreceptors regardless of how fast glucose changes
C) The retinopathy worsening was the pre-specified primary endpoint of SUSTAIN-6 and was identical with liraglutide in LEADER
D) The effect is caused by a rise in intraocular pressure from the drug
E) The effect only occurs in patients whose HbA1c is already normal at baseline
ANSWER: A
Rationale:
In SUSTAIN-6, semaglutide was associated with worsening diabetic retinopathy attributed to rapid HbA1c reduction, paralleling the early retinopathy deterioration observed with intensive insulin therapy in the DCCT (Diabetes Control and Complications Trial), where acute glycemic correction transiently destabilizes ischemic retinal vasculature.
Option B: Option B is incorrect because the mechanism is rapid glycemic correction rather than direct photoreceptor toxicity independent of the rate of change.
Option C: Option C is incorrect because the retinopathy signal was not the pre-specified primary endpoint and was not seen with liraglutide in LEADER.
Option D: Option D is incorrect because the effect is not caused by a drug-induced rise in intraocular pressure.
Option E: Option E is incorrect because the risk is greatest with a large, rapid HbA1c drop, not in patients whose baseline HbA1c is already normal.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient, he is prescribed once-weekly subcutaneous semaglutide and asks why it only needs to be injected once a week. Which structural and pharmacokinetic explanation is correct?
A) It is fused to an immunoglobulin G4 fragment crystallizable region, which is the basis of its weekly dosing
B) It is encapsulated in extended-release microspheres that release drug over 7 days
C) It is an unmodified copy of native GLP-1 that happens to resist degradation
D) It carries a potent fatty acid (C18 diacid) modification producing tight, reversible albumin binding, which extends its half-life to approximately 165 to 184 hours (about 7 days) and supports once-weekly dosing
E) It is co-formulated with SNAC, which prolongs its plasma half-life to 7 days
ANSWER: D
Rationale:
Semaglutide carries a potent fatty acid (C18 diacid) modification that produces tight, reversible binding to albumin, protecting it from renal filtration and proteolysis and extending its half-life to roughly 165 to 184 hours (about 7 days), which supports once-weekly dosing.
Option A: Option A is incorrect because immunoglobulin G4 fragment crystallizable fusion is the dulaglutide strategy, not semaglutide's.
Option B: Option B is incorrect because microsphere encapsulation describes exenatide extended-release.
Option C: Option C is incorrect because semaglutide is structurally modified for albumin binding rather than being an unmodified native GLP-1 copy.
Option E: Option E is incorrect because SNAC enables gastric absorption of the oral formulation rather than prolonging the plasma half-life of the injectable.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient, after several weeks on once-weekly semaglutide he notices the early prominent slowing of digestion has lessened, yet his overall glucose control keeps improving. Which explanation best accounts for this evolving pattern?
A) The drug is failing, and the continued improvement is coincidental
B) The gastric-emptying effect undergoes tachyphylaxis with sustained receptor stimulation, while the glucose-lowering contribution shifts toward continuous fasting glucose suppression via sustained glucagon inhibition and glucose-dependent insulin secretion, so control improves even as the prandial gastric effect wanes
C) The gastric-emptying effect intensifies over time, which is what sustains the improvement
D) The improvement reflects newly developed renal glucose excretion
E) The drug has converted to a short-acting profile, explaining the reduced gastric effect
ANSWER: B
Rationale:
With sustained stimulation from a long-acting agent, the gastric-emptying effect undergoes tachyphylaxis and the prandial slowing wanes, while the glucose-lowering contribution shifts toward continuous fasting glucose suppression via sustained glucagon inhibition and ongoing glucose-dependent insulin secretion, so control continues to improve.
Option A: Option A is incorrect because the drug is not failing; the fasting-directed mechanisms sustain the benefit.
Option C: Option C is incorrect because the gastric-emptying effect lessens rather than intensifies over time.
Option D: Option D is incorrect because GLP-1 receptor agonists do not lower glucose mainly by increasing renal glucose excretion.
Option E: Option E is incorrect because the agent remains long-acting; the declining gastric effect reflects tachyphylaxis, not conversion to a short-acting profile.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.